17
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Artificial Intelligence in Gastroenterology

      Submit here before May 31, 2024

      About Digestion: 3.2 Impact Factor I 6.4 CiteScore I 0.914 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Colorectal Liver Metastases: A Critical Review of State of the Art

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Over 50% of patients with colorectal cancer will develop liver metastases. Only a minority of patients present with technically resectable disease. Around 40% of those undergoing surgical resection are alive five years after their diagnosis compared with less than 1% for those with disseminated disease treated with systemic chemotherapy. Surgical resection remains the only possibility for long-term survival for these patients and great efforts have been made to increase the rates of resection whilst improving long-term outcomes. Summary: This review considers current technical and oncological criteria for resection, as well as targeted approaches to stratify underlying tumor biology in order to better predict long-term benefit. The role of neoadjuvant and perioperative systemic chemotherapy is critically reviewed, with suggestions for patient stratification in order to identify those who are likely to derive the greatest benefit. The key role of multidisciplinary assessment and decision making for these complex patients is also discussed. Key Messages: Surgery remains the optimal treatment for colorectal liver metastases (CRLM). Despite the curative intent of surgical resection, the majority of patients develop recurrence. Surgical strategies should therefore be adopted to maximize the potential for repeat resections in the event of recurrence. Although a number of preoperative prognostic markers have been identified, none are absolute contraindications to resection. In order to reduce postoperative recurrence, neo-adjuvant chemotherapy is now the standard of care in a number of countries. The evidence base for this approach is contentious, and the potential benefit of such a strategy is likely to be greatest in patients with high oncological risk disease. Multidisciplinary care is essential to ensure the optimal management of these complex patients. In addition, all patients with CRLM should be discussed with specialist hepatobiliary surgeons.

          Related collections

          Author and article information

          Journal
          LIC
          LIC
          10.1159/issn.1664-5553
          Liver Cancer
          S. Karger AG
          2235-1795
          1664-5553
          2017
          January 2017
          29 November 2016
          : 6
          : 1
          : 66-71
          Affiliations
          aSchool of Cancer Studies, Institute of Translational Medicine, University of Liverpool, Liverpool, bNorth Western Hepatobiliary Unit, Aintree University Hospital, Liverpool, United Kingdom, cDepartment of Surgery, University of Tokyo, Tokyo, Japan, dUniversity Hospital Carl Gustav Carus, University Cancer Center, Dresden, Germany, eDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan
          Article
          449348 PMC5159727 Liver Cancer 2017;6:66-71
          10.1159/000449348
          PMC5159727
          27995090
          19ed7f36-5d76-4c06-89ec-ef09b53ea697
          © 2016 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          Page count
          References: 27, Pages: 6
          Categories
          EWALT 2015 Conference Proceedings: Review

          Oncology & Radiotherapy,Gastroenterology & Hepatology,Surgery,Nutrition & Dietetics,Internal medicine
          Surgery,Chemotherapy,Liver cancer

          Comments

          Comment on this article